VILDAVAS-50

VILDAVAS-50 is a pharmaceutical tablet formulation containing Vildagliptin 50 mg as its active pharmaceutical ingredient. The product is listed in the Suprimeda pharmaceutical portfolio under the Anti-Diabetics category and is formulated as an oral tablet dosage form. Vildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of pharmaceutical compounds. The formulation provides a defined 50 mg strength of Vildagliptin in each tablet, allowing clear identification of the active ingredient, strength and dosage form for professional pharmaceutical requirements.

VILDAVAS-50 is presented as a conventional oral tablet formulation suitable for pharmaceutical cataloguing, institutional procurement and professional healthcare product documentation. The product identity is clearly established through its brand name, active pharmaceutical ingredient and stated strength. For B2B pharmaceutical identification, relevant descriptors include Vildagliptin 50 mg tablets, Vildagliptin tablets, DPP-4 inhibitor tablets, antidiabetic tablets, Vildagliptin formulation and pharmaceutical tablets.